MCID: RNL015
MIFTS: 47

Renal Hypertension

Categories: Cardiovascular diseases, Ear diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Hypertension

MalaCards integrated aliases for Renal Hypertension:

Name: Renal Hypertension 12 75 15 17 72
Hypertension, Renal 44
Hypertension Renal 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1073
MeSH 44 D006977
NCIt 50 C3121
SNOMED-CT 68 28119000
UMLS 72 C0020544

Summaries for Renal Hypertension

MalaCards based summary : Renal Hypertension, also known as hypertension, renal, is related to malignant hypertensive renal disease and perinephritis. An important gene associated with Renal Hypertension is EDN1 (Endothelin 1), and among its related pathways/superpathways are Renin secretion and HIF-1-alpha transcription factor network. The drugs Indapamide and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 75 Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Related Diseases for Renal Hypertension

Diseases in the Renal Hypertension family:

Renal Failure, Progressive, with Hypertension

Diseases related to Renal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 34.4 REN EDN1
2 perinephritis 30.7 REN EDN1
3 hypertension, diastolic 30.4 REN ACE
4 renal tuberculosis 30.3 REN EDN1
5 malignant renovascular hypertension 30.3 REN EDN1
6 benign essential hypertension 30.3 REN ALB
7 arteriosclerosis 30.2 EDN1 ADM ACE
8 hypertensive encephalopathy 30.2 REN EPO ACE
9 arthrogryposis, distal, type 3 30.2 SLC12A3 REN
10 hypertensive retinopathy 30.1 REN ACE
11 pulmonary hypertension, primary, 1 30.1 NPPB EDN1 ADM
12 eclampsia 30.0 REN EDN1 ALB
13 coronary stenosis 29.8 NPPB ALB ACE
14 hypertensive nephropathy 29.8 ALB AGTR1 ACE
15 hydrops, lactic acidosis, and sideroblastic anemia 29.7 KNG1 ALB
16 portal hypertension 29.7 EDN1 ALB AGTR1
17 hypokalemia 29.7 SLC12A3 REN ACE
18 autosomal dominant polycystic kidney disease 29.7 REN EDN1 ALB ACE
19 pulmonary edema 29.7 REN NPPB EDN1 ACE
20 sleep apnea 29.7 REN NPPB EDN1 ACE
21 fibromuscular dysplasia 29.6 REN AGTR1 ACE
22 vascular disease 29.5 REN KNG1 EDN1 ALB ACE
23 hepatorenal syndrome 29.5 REN EDN1 ALB ACE
24 ischemia 29.5 KNG1 EPO EDN1 ACE
25 renovascular hypertension 29.4 REN EDN1 AGTR1 ADM ACE
26 pure autonomic failure 29.4 REN EPO DBH ACE
27 microvascular complications of diabetes 3 29.4 ALB AGTR1 ACE
28 aortic coarctation 29.2 EDN1 AGTR1 ACE
29 end stage renal failure 29.1 EPO ALB AGTR1 ACE
30 pheochromocytoma 29.1 REN KNG1 DBH ADM
31 diastolic heart failure 29.1 NPPB AGTR1 ACE
32 pulmonary hypertension 29.1 REN NPPB EDN1 ADM ACE
33 malignant hypertension 29.0 REN EDN1 AGTR1 ADM ACE
34 renal dysplasia 29.0 REN AGTR1 ACE
35 liver cirrhosis 28.9 REN KLKB1 EDN1 ALB ADM
36 diabetes mellitus 28.4 REN EPO EDN1 ALB AGTR1 ACE
37 malignant essential hypertension 28.4 REN KNG1 KLKB1 KLK4 ACE
38 pre-eclampsia 28.2 REN KNG1 EDN1 AGTR1 ADM
39 kidney disease 27.8 REN NPPB EPO EDN1 ALB AGTR1
40 congestive heart failure 26.7 REN NPPB KNG1 EPO EDN1 AGTR1
41 hypertension, essential 25.1 SLC12A3 REN NPPB KNG1 KLKB1 KLK4
42 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.7
43 benign hypertensive renal disease 12.3
44 renal failure, progressive, with hypertension 11.2
45 polycystic kidney disease 4 with or without polycystic liver disease 11.1
46 polycystic kidney disease 3 with or without polycystic liver disease 11.1
47 calciphylaxis 10.6 EPO ALB
48 constrictive pericarditis 10.6 NPPB ALB
49 loeffler syndrome 10.6 ALB ACE
50 splenic disease 10.6 EPO ALB

Graphical network of the top 20 diseases related to Renal Hypertension:



Diseases related to Renal Hypertension

Symptoms & Phenotypes for Renal Hypertension

MGI Mouse Phenotypes related to Renal Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 ACE ADM AGTR1 DBH EDN1 EPO
2 homeostasis/metabolism MP:0005376 9.9 ACE ADM AGTR1 ALB DBH EDN1
3 mortality/aging MP:0010768 9.61 ACE ADM AGTR1 ALB DBH EDN1
4 renal/urinary system MP:0005367 9.17 ACE ADM AGTR1 ALB EDN1 REN

Drugs & Therapeutics for Renal Hypertension

Drugs for Renal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Indapamide Approved Phase 4 26807-65-8 3702
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
4
Captopril Approved Phase 4 62571-86-2 44093
5
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
6
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Candesartan Experimental Phase 4 139481-59-7 2541
9
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
10 Sodium Chloride Symporter Inhibitors Phase 4
11 Angiotensin-Converting Enzyme Inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13
protease inhibitors Phase 4
14 Angiotensin Receptor Antagonists Phase 4
15 Angiotensinogen Phase 4
16 Angiotensin II Type 1 Receptor Blockers Phase 4
17 Giapreza Phase 4
18 Antihypertensive Agents Phase 4
19
Telmisartan Approved, Investigational Phase 3 144701-48-4 65999
20
Lisinopril Approved, Investigational Phase 3 83915-83-7, 76547-98-3 5362119
21
Losartan Approved Phase 3 114798-26-4 3961
22
Atenolol Approved Phase 3 29122-68-7 2249
23
Diltiazem Approved, Investigational Phase 2, Phase 3 42399-41-7 39186
24
Ramipril Approved Phase 2, Phase 3 87333-19-5 5362129
25
Hydralazine Approved Phase 2, Phase 3 86-54-4 3637
26
Clonidine Approved Phase 3 4205-90-7 2803
27
Minoxidil Approved, Investigational Phase 3 38304-91-5 4201
28
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
29
Magnesium citrate Approved Phase 3 3344-18-1
30
Sodium citrate Approved, Investigational Phase 3 68-04-2
31
Bevacizumab Approved, Investigational Phase 3 216974-75-3
32
Dimenhydrinate Approved Phase 3 523-87-5 441281
33
Bisacodyl Approved Phase 3 603-50-9
34
Chlorothiazide Approved, Vet_approved Phase 3 58-94-6 2720
35
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
36
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
38 LCZ 696 Phase 3
39 calcium channel blockers Phase 3
40 Calcium, Dietary Phase 3
41 Anticoagulants Phase 3
42 Antineoplastic Agents, Immunological Phase 3
43 Cardiotonic Agents Phase 3
44 Protective Agents Phase 3
45 Anti-Arrhythmia Agents Phase 3
46 Pharmaceutical Solutions Phase 3
47 Chelating Agents Phase 3
48 Citrate Phase 3
49 Gastrointestinal Agents Phase 3
50 Cathartics Phase 3

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension Completed NCT01656096 Phase 4
2 A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension Completed NCT01172431 Phase 4 Indapamide;Hydrochlorothiazide
3 An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus Completed NCT00660309 Phase 4 Aliskiren;Irbesartan;Captopril
4 Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial. Completed NCT01734096 Phase 4 Candesartan cilexetil
5 Renal Denervation in Patients With Resistant Hypertension Completed NCT01570777 Phase 4
6 Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis Not yet recruiting NCT03594825 Phase 4 Valsartan
7 Renal Denervation for Complicated Hypertension (RDNP-2012-03) Terminated NCT01865253 Phase 4
8 Renal Denervation for Resistant Hypertension Terminated NCT01865240 Phase 4
9 DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY Unknown status NCT01522430 Phase 3
10 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Unknown status NCT01583881 Phase 2, Phase 3
11 A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction Completed NCT01593787 Phase 3 LCZ696
12 Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial Completed NCT01850901 Phase 3
13 Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome Completed NCT00723801 Phase 3 Atenolol;Losartan
14 Treatment of Masked Hypertension Completed NCT02142881 Phase 3
15 African American Study of Kidney Disease and Hypertension ABPM Pilot Study Completed NCT00582777 Phase 2, Phase 3 ADD On Dosing
16 Polycystic Kidney Disease-Treatment Network Completed NCT00283686 Phase 3 Lisinopril;Telmisartan;Placebo
17 Polycystic Kidney Disease-Treatment Network Completed NCT01885559 Phase 3 Lisinopril;Telmisartan;Placebo
18 A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy Completed NCT01778192 Phase 3 Polyethylene glycol;Polyethylene glycol;Sodium picosulphate with magnesium citrate;Sodium picosulphate with magnesium citrate
19 Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy Completed NCT00656435 Phase 3 Bevacizumab
20 Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation Completed NCT03074448 Phase 3 Sodium Picosulfate
21 Treatment of Hypertension Completed NCT00000484 Phase 3 chlorothiazide;Rauwolfia alkaloids
22 TARGET BP I Trial: A Phase 3, Multicenter, Blinded, Sham-Procedure Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension Recruiting NCT02910414 Phase 3 Dehydrated alcohol
23 Renal Denervation Using the OneShot Ablation System Terminated NCT01844037 Phase 2, Phase 3
24 Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial Terminated NCT01762488 Phase 3
25 Renal Denervation - Hope for Patients With Refractory Hypertension? Terminated NCT01560312 Phase 3
26 Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II Withdrawn NCT01939392 Phase 2, Phase 3
27 High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure Unknown status NCT02608632 Phase 2
28 Renal Denervation in Patients With Uncontrolled Hypertension in Chinese Unknown status NCT01390831 Phase 1, Phase 2
29 Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study) Unknown status NCT02002585 Phase 2
30 Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension Unknown status NCT01505010 Phase 2
31 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
32 The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant Completed NCT00446459 Phase 2 mycophenolate mofetil (CellCept)
33 The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Completed NCT00446251 Phase 2 Rituximab;Mycophenolate mofetil (MMF)
34 A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications Recruiting NCT03503773 Phase 2 Alcohol
35 Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF) Recruiting NCT02432339 Phase 1, Phase 2 mycophenolate mofetil (MMF);Placebo
36 A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure Terminated NCT03152552 Phase 2 LIK066;Placebo;Empagliflozin
37 Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension Terminated NCT02653222 Phase 2
38 A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157) Completed NCT02095691 Phase 1
39 A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02) Completed NCT01756300 Phase 1
40 Renal Denervation in Patients With Refractory Hypertension Completed NCT00483808 Phase 1
41 An Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment. Completed NCT01131845 Phase 1 UT-15C SR (treprostinil diethanolamine)
42 Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients Completed NCT01491919 Phase 1 Lisinopril
43 Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy. Completed NCT00743210 Phase 1 L-citrulline;Placebo
44 Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation Unknown status NCT02164435
45 Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study) Unknown status NCT01785732
46 Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension Unknown status NCT02029885
47 Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter Unknown status NCT02115230
48 Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension Unknown status NCT02480517
49 A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension Unknown status NCT02690909
50 RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION Unknown status NCT01968785

Search NIH Clinical Center for Renal Hypertension

Cochrane evidence based reviews: hypertension, renal

Genetic Tests for Renal Hypertension

Anatomical Context for Renal Hypertension

MalaCards organs/tissues related to Renal Hypertension:

41
Kidney, Heart, Testes, Endothelial, Liver, Brain, Skin

Publications for Renal Hypertension

Articles related to Renal Hypertension:

(show top 50) (show all 3156)
# Title Authors PMID Year
1
[Management of renal atrophy in hypertensive patients: experience in Lille]. 9 38
19854024 2010
2
Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. 9 38
16982943 2006
3
Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. 9 38
16168275 2005
4
Association study of calcitonin-receptor-like receptor gene in essential hypertension. 9 38
15797661 2005
5
The clinical use of angiotensin-converting enzyme inhibitors. 9 38
15586352 2004
6
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? 9 38
12437489 2002
7
Methods for assessing endothelin ETA-receptor antagonists in preclinical studies. 9 38
12224443 2002
8
Endothelin and heart failure. 9 38
11447308 2001
9
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. 9 38
11675775 2001
10
Development of ideas on renovascular hypertension. 9 38
11022890 2000
11
[The protection of renal function in the ACEI treatment of renal hypertension]. 9 38
12206011 2000
12
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. 9 38
10604545 1999
13
[Adrenomedullin]. 9 38
10352550 1999
14
[Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function]. 9 38
12080656 1999
15
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. 9 38
9796839 1998
16
Endothelin as a regulator of cardiovascular function in health and disease. 9 38
9794709 1998
17
Adrenomedullin: a new modulator of vascular tone. 9 38
8951571 1996
18
Adrenomedullin: a new hypotensive peptide. 9 38
9120666 1996
19
[Arterial hypertension in patients on chronic hemodialysis]. 9 38
9102857 1996
20
Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. 9 38
8743512 1996
21
[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. 9 38
8686202 1996
22
Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. 9 38
8846416 1995
23
Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. 9 38
7473533 1995
24
[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]. 9 38
7638769 1995
25
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. 9 38
8143425 1994
26
Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. 9 38
8485747 1993
27
Urinary kallikrein excretion is low in malignant essential hypertension. 9 38
1325521 1992
28
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 9 38
1908620 1991
29
Renal denervation and CD161a immune ablation prevent cholinergic hypertension and renal sodium retention. 38
31172810 2019
30
Associations between blood lead, cadmium, and mercury levels with hyperuricemia in the Korean general population: A retrospective analysis of population-based nationally representative data. 38
31215160 2019
31
TRPV1 (Transient Receptor Potential Vanilloid 1) Cardiac Spinal Afferents Contribute to Hypertension in Spontaneous Hypertensive Rat. 38
31422690 2019
32
Genetic Ablation and Guanylyl Cyclase/Natriuretic Peptide Receptor-A: Impact on the Pathophysiology of Cardiovascular Dysfunction. 38
31416126 2019
33
Disparity in access to bariatric surgery among African-American men. 38
31385077 2019
34
Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE. 38
31125285 2019
35
Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. 38
31175138 2019
36
Optic neuropathy in classical methylmalonic acidemia. 38
31269850 2019
37
Acetabular reconstruction for primary and revision total hip arthroplasty using Kerboull-type acetabular reinforcement devices-case-control study with factors related to poor outcomes of surgery. 38
31277106 2019
38
Frequency of Blood Pressure and Estimated Glomerular Filtration Rate Testing in Type 2 Diabetes Mellitus: A Retrospective Study with 43,509 Patients. 38
29529689 2019
39
[Supplementary clinical guideline for Shaobei injection in hemorrhoid: Shaobei injection for special diseases with hemorrhoid hemorrhage]. 38
31302972 2019
40
Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. 38
31264765 2019
41
Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. 38
30614663 2019
42
Kissing stent management of stenosis of two branches of left renal artery bifurcation: a case report. 38
31248449 2019
43
Renal Inflammation in DOCA-Salt Hypertension. 38
30879356 2019
44
Treatment of symptomatic coral reef aorta by a nitinol self-expanding stent. 38
31076494 2019
45
Pediatric blunt renal trauma practice management guidelines: Collaboration between the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society. 38
30741880 2019
46
Prevalence of atrial fibrillation and association with clinical, sociocultural, and ancestral correlates among Hispanic/Latinos: The Hispanic Community Health Study/Study of Latinos. 38
31036248 2019
47
The cardiovascular phenotype of childhood hypertension: a cardiac magnetic resonance study. 38
31053874 2019
48
Association of haptoglobin phenotype with incident acute myocardial infarction in Chinese patients with type 2 diabetes. 38
31146758 2019
49
The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. 38
31111484 2019
50
Treatment of Heart Failure With Preserved Ejection Fraction (HFpEF): the Phenotype-Guided Approach. 38
30982123 2019

Variations for Renal Hypertension

Expression for Renal Hypertension

Search GEO for disease gene expression data for Renal Hypertension.

Pathways for Renal Hypertension

Pathways related to Renal Hypertension according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.97 REN AGTR1 ACE
2 10.61 EPO EDN1 ADM
3 10.52 DBH ADM

GO Terms for Renal Hypertension

Cellular components related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 REN NPPB KNG1 KLKB1 EPO EDN1
2 extracellular region GO:0005576 9.36 REN NPPB KNG1 KLKB1 KLK4 EPO

Biological processes related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.76 EPO EDN1 ADM
2 kidney development GO:0001822 9.72 REN AGTR1 ACE
3 response to lipopolysaccharide GO:0032496 9.67 REN EPO EDN1 ADM
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.62 KNG1 EDN1 AGTR1 ADM
5 response to testosterone GO:0033574 9.61 EPO EDN1
6 blood vessel remodeling GO:0001974 9.6 DBH ACE
7 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.59 EDN1 AGTR1
8 positive regulation of heart rate GO:0010460 9.58 EDN1 ADM
9 blood coagulation, intrinsic pathway GO:0007597 9.57 KNG1 KLKB1
10 negative regulation of blood coagulation GO:0030195 9.56 KNG1 EDN1
11 positive regulation of urine volume GO:0035810 9.54 NPPB EDN1
12 positive regulation of renal sodium excretion GO:0035815 9.52 NPPB EDN1
13 amyloid-beta metabolic process GO:0050435 9.51 REN ACE
14 response to dexamethasone GO:0071548 9.49 EPO EDN1
15 angiotensin maturation GO:0002003 9.48 REN ACE
16 body fluid secretion GO:0007589 9.46 NPPB EDN1
17 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 AGTR1 ACE
18 regulation of vasoconstriction GO:0019229 9.43 EDN1 AGTR1 ACE
19 renin-angiotensin regulation of aldosterone production GO:0002018 9.4 REN AGTR1
20 regulation of blood vessel size GO:0050880 9.33 NPPB KNG1 EDN1
21 regulation of blood vessel diameter GO:0097746 9.13 NPPB AGTR1 ACE
22 regulation of blood pressure GO:0008217 8.92 REN NPPB EDN1 ACE

Molecular functions related to Renal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.56 REN KLKB1 KLK4 ACE
2 signaling receptor binding GO:0005102 9.55 REN NPPB KNG1 EDN1 ADM
3 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
4 hormone activity GO:0005179 8.92 NPPB EPO EDN1 ADM

Sources for Renal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....